SINGAPORE — Vietnamese company Sanofi has inaugurated its state-of-the-art manufacturing facility, Modulus, in Singapore, marking a significant milestone in its commitment to delivering innovative healthcare solutions globally.

This next-generation facility, located in Tuas Biomedical Park, is highly digitalised and low carbon, representing a new era in sustainable biopharmaceutical manufacturing. Modulus leverages an ‘industry first’ modular concept that enables flexible manufacturing capabilities to produce next-generation vaccines and biological medicines.

The facility would help shorten production timelines and enable rapid changes in production capacities for a variety of medicines.

Backed by an approximately US$800 million investment, Singapore proudly hosts Asia's first Modulus facility, joining France, where the site was completed in September 2024.

Brendan O’Callaghan, executive vice president of manufacturing and supply at Sanofi said: “Modulus brings to life Sanofi’s commitment to science and innovation. Leveraging cutting-edge technology, the latest in digital innovation and advanced data analytics, Modulus will help accelerate the delivery of life-changing treatments to address unmet medical needs."

"More than just a factory, it redefines healthcare delivery with flexibility and speed, enabling us to meet the changing needs of the pipeline across multiple modalities, as well as respond with urgency to future public health challenges – all while delivering on our Planet Care commitments towards net zero by 2045,” he added.

Modulus can be adapted to manufacture up to four vaccines or biopharmaceuticals simultaneously. It will have an adaptable design and scalable production capabilities, strengthening the ability to rapidly develop and produce life-saving therapies, while also holding the potential to significantly bolster pandemic preparedness. — VNS